Benitec Biopharma sets price at 13-13.06 $

Benitec Biopharma, which is developing gene therapies for hepatitis C based on RNA interference, announced terms for its IPO on Monday.

The Balmain, Australia-based company plans to raise $65 million by offering 5 million shares at a price range of $13.06 to $13.06. At the midpoint of the proposed range, Benitec Biopharma would valued at $141 million.